Recent double-blind, randomized, controlled trials reported that human umbilical cord-derived mesenchymal stem cell (MSC) infusions in COVID-19 patients with acute respiratory distress syndrome (ARDS) could diminish cytokine storm and lung damage. While these outcomes are significant, additional phase II/III trials are required to validate the efficacy of MSCs to improve the survival of COVID-19 patients with ARDS. Future studies also need to assess the efficacy of MSCs to prevent long COVID.
All Keywords
【저자키워드】 Respiratory distress syndrome, Mesenchymal stem cells, 【초록키워드】 Efficacy, ARDS, Cytokine storm, Trial, outcome, COVID, survival, acute respiratory distress, MSC, COVID-19 patient, double-blind, lung damage, syndrome, randomized, controlled trial, while, Future, recent, Prevent, Cell, IMPROVE, reported, required, umbilical, 【제목키워드】 Efficacy, ARDS, COVID-19 patient, reducing mortality, cell infusion,
【저자키워드】 Respiratory distress syndrome, Mesenchymal stem cells, 【초록키워드】 Efficacy, ARDS, Cytokine storm, Trial, outcome, COVID, survival, acute respiratory distress, MSC, COVID-19 patient, double-blind, lung damage, syndrome, randomized, controlled trial, while, Future, recent, Prevent, Cell, IMPROVE, reported, required, umbilical, 【제목키워드】 Efficacy, ARDS, COVID-19 patient, reducing mortality, cell infusion,